Industry: Drug Manufacturers #pharmaceutical #research

Posted On Apr 23 2017 by

#drug manufacturers # Drug Manufacturers – Major The pharmaceutical industry consists of companies that research, develop, market, and distribute drugs for nearly every therapeutic need. Drug sales from the 65 largest pharmaceuticals totaled $606 billion in 2007 and continues to grow. [1] Commercial drug companies are driven by research and patent protection. Developing a drug requires an enormous amount of investment in technology, materials, and time, and can be a risky venture for the company. However, after a new drug is successfully developed, thoroughly tested, and patented, it may be potentially very lucrative, especially if it addresses a common health …


Drug Store News #jobs #in #pharmaceutical #companies

Posted On Apr 23 2017 by

#pharmacy industry news # The offices of Drug Store News will be closed for the Labor Day holiday weekend. We will resume publishing on Sept. 6. The Drug Store News team wishes you and your family a happy holiday! The multi-year contract, beginning in October, includes distribution of key product categories tailored specifically to fit the needs of Fred s unique format of a discount retailer and pharmacy. Walmart has unveiled its annual top toy list, chosen by hundreds of kids. Costco reported a 2% increase in same store sales for August and net sales of $8.9 billion. At its …


Novartis pharma head leaves as drug maker splits operations #small #pharma #companies

Posted On Apr 22 2017 by

#novartis pharma # Novartis pharma head leaves as drug maker splits operations Underscoring its increasing emphasis on oncology, Novartis is splitting its prescription drug business into two organizations and hired Paul Hudson, who heads North American operations for AstraZeneca, to lead the pharmaceutical business. The newly created oncology unit, meanwhile, will be run by Bruno Strigini, who already runs the cancer-drug business. The move comes a year after Novartis purchased a portfolio of oncology medicines from GlaxoSmithKline as part of an asset swap. But Novartis is also contending with declining sales of its Gleevec cancer medicine, which has been a …


Allergan’s Actavis recalls nearly 600, 000 bottles of ADHD drug #bsp #pharma

Posted On Apr 22 2017 by

#actavis pharma manufacturing # Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug Teva ($TEVA) is expecting to close on its buyout of Allergan’s generic drug business, but for now Actavis is still Allergan’s, for better or worse. That means that Allergan ($AGN) is responsible for the recall of more than 50 lots, consisting of nearly 600,000 bottles, of its copy of the ADHD drug Adderall. According to the most recent FDA Enforcement Report, Actavis is voluntarily recalling 54 lots involving four different dose forms of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets after they failed tests …


Drug Interactions Checker – Check Your Brand and Generic Drugs #dr #reddy #pharma

Posted On Apr 22 2017 by

#pharmaceutical drugs # Interaction is unlikely, minor, or nonsignificant Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions. Please check with a physician if you have health questions or concerns. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect. Drug Interactions Drug interactions overview Whenever two or more drugs are being taken, there is a chance that …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #d #pharma

Posted On Apr 21 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Background on Drug Advertising #pharma

Posted On Apr 21 2017 by

#pharmaceutical advertising # Background on Drug Advertising The Food and Drug Administration (FDA) protects public health by assuring the safety, effectiveness, and security of a wide range of products, including human prescription drugs. We also advance public health by helping people get the accurate, science-based information they need to use medicines appropriately and improve their health. We serve the public health and welfare in many ways. One way is overseeing the approval and marketing of prescription drugs. Our authority is based on a number of federal laws, including the Federal Food, Drug, and Cosmetic Act. Among other areas, this law …


Drug company R – D: Nowhere near $1 billion #taro #pharma

Posted On Apr 21 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Specialty Pharmacy News – Drug Store News #barr #pharma

Posted On Apr 20 2017 by

#pharmacy news # Specialty Pharmacy News Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the …


Specialists in pharmaceutical contract manufacturers, clinical drug manufacturing and contract manufacturing pharma #macleods #pharma

Posted On Apr 20 2017 by

#pharmaceutical contract manufacturing # At Therapure Biopharma Inc. we’re specialists in biologics. In our three divisions, our passion for quality and patient safety underpins everything we do. Biologics Contract Development and ManufacturingTherapure Biomanufacturing is more than a CMO (contract manufacturing organization)—we’re a CDMO (contract development and manufacturing organization). We understand the requirements for commercializing protein therapeutics. And we understand the importance of the development process. Most importantly, we understand each client’s needs. If you’re looking for a biologics-focused CDMO with a track record of successful process development, cGMP manufacturing (drug substance) and/or aseptic fill/ finish (drug product) services, please click …